| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.80 [0.72, 0.89] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.73 [0.64, 0.83] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| progression or deaths (PFS) | 1.06 [0.83, 1.35] | | < 1 | | 81% | 3 studies (3/-) | 31.7 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 0.80 [0.36, 1.78] | | > 1 | | 91% | 3 studies (3/-) | 29.3 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.31 [0.22, 0.44] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 1.00 [0.69, 1.46] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 1.02 [0.69, 1.50] | | < 1 | | 0% | 2 studies (2/-) | 46.1 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.68 [0.20, 2.35] | | < 1 | | 95% | 2 studies (2/-) | 72.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.22 [0.05, 0.93] | | < 1 | | 93% | 3 studies (3/-) | 98.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.29 [0.06, 1.37] | | < 1 | | 98% | 3 studies (3/-) | 94.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 0.99 [0.37, 2.63] | | < 1 | | 43% | 3 studies (3/-) | 50.9 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 1.20 [0.55, 2.62] | | < 1 | | 0% | 1 study (1/-) | 32.3 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.28 [0.53, 3.10] | | < 1 | | 0% | 1 study (1/-) | 29.1 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Acute kidney injury TRAE (grade 3-4) | 1.91 [0.06, 57.09] | | < 1 | | 0% | 1 study (1/-) | 35.7 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 1.29 [0.15, 11.09] | | < 1 | | 0% | 3 studies (3/-) | 40.8 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.19 [0.01, 2.67] | | < 1 | | 93% | 3 studies (3/-) | 88.9 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.47 [0.12, 1.88] | | < 1 | | 47% | 3 studies (3/-) | 85.8 % | some concern | not evaluable | moderate | non important | - |
| Blood and lymphatic system disorders TRAE (grade 3-4) | 0.12 [0.01, 2.59] | | < 1 | | 97% | 3 studies (3/-) | 91.0 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 1.30 [0.15, 11.18] | | < 1 | | 0% | 3 studies (3/-) | 40.5 % | some concern | not evaluable | moderate | non important | - |
| Cardiac disorders TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Chills TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 0.99 [0.27, 3.68] | | < 1 | | 0% | 3 studies (3/-) | 50.5 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.74 [0.09, 6.36] | | < 1 | | 0% | 3 studies (3/-) | 60.7 % | some concern | not evaluable | moderate | non important | - |
| Cough TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.71 [0.11, 4.40] | | < 1 | | 61% | 3 studies (3/-) | 64.4 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.74 [0.16, 3.32] | | < 1 | | 47% | 3 studies (3/-) | 65.5 % | some concern | not evaluable | moderate | non important | - |
| Dyspepsia TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 3.83 [0.17, 85.33] | | < 1 | | 0% | 1 study (1/-) | 20.1 % | NA | not evaluable | | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 3.02 [0.46, 19.73] | | < 1 | | 0% | 3 studies (3/-) | 12.5 % | some concern | not evaluable | moderate | non important | - |
| Epistaxis TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Eye disorders TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.98 [0.26, 3.68] | | < 1 | | 72% | 3 studies (3/-) | 51.4 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.05 [0.00, 0.79] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | non important | - |
| Gastritis TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 0.17 [0.03, 0.80] | | < 1 | | 78% | 2 studies (2/-) | 98.7 % | some concern | not evaluable | moderate | non important | - |
| General disorders and administration site conditions TRAE (grade 3-4) | 0.61 [0.15, 2.52] | | < 1 | | 90% | 3 studies (3/-) | 75.2 % | some concern | not evaluable | moderate | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 1.91 [0.06, 57.09] | | < 1 | | 0% | 1 study (1/-) | 35.7 % | NA | not evaluable | | non important | - |
| Headache TRAE (grade 3-4) | 0.47 [0.02, 14.21] | | < 1 | | 0% | 1 study (1/-) | 66.4 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.59 [0.39, 17.34] | | < 1 | | 0% | 3 studies (3/-) | 16.4 % | some concern | not evaluable | moderate | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 0.95 [0.06, 15.29] | | < 1 | | 0% | 1 study (1/-) | 51.4 % | NA | not evaluable | | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Hypertension TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.29 [0.15, 11.09] | | < 1 | | 0% | 3 studies (3/-) | 40.8 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 2.00 [0.18, 22.10] | | < 1 | | 0% | 2 studies (2/-) | 28.8 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.47 [0.11, 19.19] | | < 1 | | 0% | 2 studies (2/-) | 38.5 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 0.31 [0.03, 3.04] | | < 1 | | 0% | 1 study (1/-) | 84.0 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.16 [0.01, 3.15] | | < 1 | | 0% | 1 study (1/-) | 88.4 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.36 [0.12, 1.06] | | < 1 | | 0% | 3 studies (3/-) | 96.8 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.15 [0.02, 1.03] | | < 1 | | 60% | 3 studies (3/-) | 97.3 % | some concern | not evaluable | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.47 [0.02, 14.21] | | < 1 | | 0% | 1 study (1/-) | 66.4 % | NA | not evaluable | | non important | - |
| Metabolism and nutrition disorders TRAE (grade 3-4) | 0.47 [0.19, 1.17] | | < 1 | | 79% | 3 studies (3/-) | 94.8 % | some concern | not evaluable | moderate | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.42 [0.05, 3.31] | | < 1 | | 85% | 3 studies (3/-) | 79.5 % | some concern | not evaluable | moderate | non important | - |
| Musculoskeletal and connective tissue disorders TRAE (grade 3-4) | 1.91 [0.06, 57.09] | | < 1 | | 0% | 1 study (1/-) | 35.7 % | NA | not evaluable | | non important | - |
| Myalgia TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.49 [0.11, 19.48] | | < 1 | | 0% | 2 studies (2/-) | 38.1 % | some concern | not evaluable | moderate | non important | - |
| Myositis TRAE (grade 3-4) | 0.50 [0.05, 5.51] | | < 1 | | 0% | 2 studies (2/-) | 71.4 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.31 [0.03, 2.80] | | < 1 | | 65% | 3 studies (3/-) | 85.1 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 2.32 [0.20, 26.51] | | < 1 | | 0% | 2 studies (2/-) | 25.0 % | some concern | not evaluable | moderate | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 0.47 [0.04, 5.26] | | < 1 | | 0% | 1 study (1/-) | 72.7 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.08 [0.00, 1.60] | | < 1 | | 89% | 3 studies (3/-) | 94.9 % | some concern | not evaluable | moderate | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.49 [0.11, 19.48] | | < 1 | | 0% | 2 studies (2/-) | 38.1 % | some concern | not evaluable | moderate | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.16 [0.01, 3.15] | | < 1 | | 0% | 1 study (1/-) | 88.4 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.91 [0.06, 57.09] | | < 1 | | 0% | 1 study (1/-) | 35.7 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.18 [0.74, 6.38] | | < 1 | | 0% | 3 studies (3/-) | 7.8 % | some concern | not evaluable | moderate | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Pruritus generalised TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.24 [0.01, 5.27] | | < 1 | | 0% | 1 study (1/-) | 81.6 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.13 [0.04, 0.50] | | < 1 | | 25% | 3 studies (3/-) | 99.9 % | some concern | not evaluable | moderate | non important | - |
| Renal and urinary disorders TRAE (grade 3-4) | 1.91 [0.06, 57.09] | | < 1 | | 0% | 1 study (1/-) | 35.7 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 1.44 [0.40, 5.16] | | < 1 | | 0% | 1 study (1/-) | 28.9 % | NA | not evaluable | | non important | - |
| Sepsis TRAE (grade 3-4) | 0.24 [0.01, 5.27] | | < 1 | | 0% | 1 study (1/-) | 81.6 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 0.27 [0.12, 0.61] | | < 1 | | 30% | 3 studies (3/-) | 99.9 % | some concern | not evaluable | moderate | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 0.17 [0.06, 0.50] | | < 1 | | 27% | 2 studies (2/-) | 99.9 % | some concern | not evaluable | moderate | non important | - |
| Skin exfoliation TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Stevens-Johnson syndrome TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.26 [0.02, 4.41] | | < 1 | | 86% | 3 studies (3/-) | 82.3 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.18 [0.02, 2.20] | | < 1 | | 83% | 3 studies (3/-) | 90.8 % | some concern | not evaluable | moderate | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.00 [0.06, 15.99] | | < 1 | | 0% | 2 studies (2/-) | 50.1 % | some concern | not evaluable | moderate | non important | - |
| Uveitis TRAE (grade 3-4) | 1.00 [0.06, 15.99] | | < 1 | | 0% | 2 studies (2/-) | 50.1 % | some concern | not evaluable | moderate | non important | - |
| Vascular disorders TRAE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.52 [0.04, 7.08] | | < 1 | | 66% | 2 studies (2/-) | 68.6 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased TRAE (grade 3-4) | 1.38 [0.26, 7.18] | | < 1 | | 0% | 3 studies (3/-) | 35.2 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.31 [0.08, 1.14] | | < 1 | | 0% | 2 studies (2/-) | 96.1 % | some concern | not evaluable | moderate | non important | - |
| Acute kidney injury AE (grade 3-4) | 2.26 [0.69, 7.40] | | < 1 | | 0% | 2 studies (2/-) | 8.9 % | some concern | not evaluable | moderate | non important | - |
| Anaemia AE (grade 3-4) | 0.64 [0.10, 4.24] | | < 1 | | 96% | 2 studies (2/-) | 67.9 % | some concern | not evaluable | moderate | non important | - |
| Asthenia AE (grade 3-4) | 0.62 [0.19, 2.01] | | < 1 | | 53% | 2 studies (2/-) | 78.5 % | some concern | not evaluable | moderate | non important | - |
| Back pain AE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Blood and lymphatic system disorders AE (grade 3-4) | 0.38 [0.03, 4.87] | | < 1 | | 99% | 2 studies (2/-) | 76.8 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite AE (grade 3-4) | 0.67 [0.14, 3.15] | | < 1 | | 75% | 2 studies (2/-) | 69.3 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea AE (grade 3-4) | 0.56 [0.13, 2.37] | | < 1 | | 60% | 2 studies (2/-) | 78.4 % | some concern | not evaluable | moderate | non important | - |
| Dizziness AE (grade 3-4) | 0.95 [0.02, 48.13] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 1.82 [0.66, 4.99] | | < 1 | | 0% | 2 studies (2/-) | 12.3 % | some concern | not evaluable | moderate | non important | - |
| Fatigue AE (grade 3-4) | 0.99 [0.40, 2.45] | | < 1 | | 63% | 2 studies (2/-) | 50.8 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia AE (grade 3-4) | 0.27 [0.01, 13.91] | | < 1 | | 87% | 2 studies (2/-) | 73.8 % | some concern | not evaluable | moderate | non important | - |
